EXECUTIVE SUMMARY: This analysis, unique to THE DARK REPORT, contrasts the decision of Palmetto GBA to distinguish between “hotspot” tumor panels (meaning those targeting 5 to 50 genes and 51 or more genes) versus “sequencing” tumor panels in coding and pricing NGS test panels, with simpler approaches used by other health insurers. Understanding these differences …
Payers Using Two Approaches To Price Molecular and Genetic Tests Read More »
